Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Conditions
Interventions
IW-3300 rectal foam
Placebo
Locations
53
United States
Urology Associates of Mobile
Mobile, Alabama, United States
Velocity Clinical Research
Mobile, Alabama, United States
Ironwood Research Center
Scottsdale, Arizona, United States
Urological Associates of Southern Arizona
Tucson, Arizona, United States
Arkansas Urology
Little Rock, Arkansas, United States
Ironwood Research Center
Fresno, California, United States
Start Date
March 28, 2023
Primary Completion Date
January 23, 2025
Completion Date
February 6, 2025
Last Updated
February 28, 2025
NCT07391306
NCT05737121
NCT00389142
NCT05726786
NCT05149573
NCT05279963
Lead Sponsor
Ironwood Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions